000			03788nam a22005417a 4500
008			181116s20182018 xxu||||| |||| 00| 0 eng d
022			_a1007-9327
024			_a10.3748/wjg.v24.i41.4691 [doi]
024			_aPMC6224476 [pmc]
040			_aOvid MEDLINE(R)
099			_a30416316
245			_aEnd-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients.
251			_aWorld Journal of Gastroenterology. 24(41):4691-4697, 2018 Nov 07.
252			_aWorld J Gastroenterol. 24(41):4691-4697, 2018 Nov 07.
253			_aWorld journal of gastroenterology
260			_c2018
260			_fFY2019
265			_sppublish
266			_d2018-11-16
520			_aAIM: To determine if end-stage renal disease (ESRD) is a risk factor for post endoscopic retrograde cholangiopancreatography (ERCP) adverse events (AEs).
520			_aCONCLUSION: ESRD is a risk factor for post-ERCP AEs and is associated with higher hospital mortality. Careful selection and close monitoring is warranted to improve outcomes.
520			_aMETHODS: We performed a retrospective cohort study using the Nationwide Inpatient Sample (NIS) 2011-2013. We identified adult patients who underwent ERCP using the International Classification of Diseases 9<sup>th</sup> Revision (ICD-9-CM). Included patients were divided into three groups: ESRD, chronic kidney disease (CKD), and control. The primary outcome was post-ERCP AEs including pancreatitis, bleeding, and perforation determined based on specific ICD-9-CM codes. Secondary outcomes were length of hospital stay, in-hospital mortality, and admission cost. AEs and mortality were compared using multivariate logistic regression analysis.
520			_aRESULTS: There were 492175 discharges that underwent ERCP during the 3 years. The ESRD and CKD groups contained 7347 and 39403 hospitalizations respectively, whereas the control group had 445424 hospitalizations. Post-ERCP pancreatitis (PEP) was significantly higher in the ESRD group (8.3%) compared to the control group (4.6%) with adjusted odd ratio (aOR) = 1.7 (95%CI: 1.4-2.1, <sup>a</sup> P < 0.001). ESRD was associated with significantly higher ERCP-related bleeding (5.1%) compared to the control group 1.5% (aOR = 1.86, 95%CI: 1.4-2.4, <sup>a</sup> P < 0.001). ESRD had increased hospital mortality 7.1% vs 1.15% in the control OR = 6.6 (95%CI: 5.3-8.2, <sup>a</sup> P < 0.001), longer hospital stay with adjusted mean difference (aMD) = 5.9 d (95%CI: 5.0-6.7 d, <sup>a</sup> P < 0.001) and higher hospitalization charges aMD = _+82064 (95%CI: _68221- _95906, <sup>a</sup> P < 0.001).
546			_aEnglish
650			_a*Cholangiopancreatography, Endoscopic Retrograde/ae [Adverse Effects]
650			_a*Kidney Failure, Chronic/co [Complications]
650			_a*Pancreatitis/ep [Epidemiology]
650			_a*Postoperative Hemorrhage/ep [Epidemiology]
650			_aAged
650			_aFemale
650			_aHospital Mortality
650			_aHumans
650			_aLength of Stay/ec [Economics]
650			_aLength of Stay/sn [Statistics & Numerical Data]
650			_aMale
650			_aMiddle Aged
650			_aPancreatitis/et [Etiology]
650			_aPostoperative Hemorrhage/et [Etiology]
650			_aRetrospective Studies
650			_aRisk Factors
651			_aMedStar Washington Hospital Center
656			_aMedicine/Gastroenterology
657			_aJournal Article
700			_aCho, Won K
790			_aAbu Dayyeh BK, Bazerbachi F, Chandrasekhara V, Cho WK, Haffar S, Levy MJ, Martin JA, Petersen BT, Sawas T, Topazian MD
856			_uhttps://dx.doi.org/10.3748/wjg.v24.i41.4691 _zhttps://dx.doi.org/10.3748/wjg.v24.i41.4691
942			_cART _dArticle
999			_c3905 _d3905